Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men
Free accessResearch articleFirst published online November, 2010
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men
Antiretroviral therapy is associated with metabolic complications, including dyslipidaemia, body fat changes and insulin resistance. Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals.
Methods
HIV-type-1-positive male participants were randomized to receive tenofovir disoproxil fumarate and lamivudine, with either fosamprenavir (FPV)/ritonavir or lopinavir (LPV)/ritonavir twice daily. A hyperinsulinaemic euglycaemic clamp was performed at baseline and at 2 weeks after commencing treatment. The homeostasis model assessment index for insulin resistance (HOMA-IR) was also calculated at these time points. Changes in lipids and lipoprotein subfractions (by nuclear magnetic resonance spectroscopy) were assessed. A pharmacokinetic assessment was undertaken at week 2.
Results
A total of 27 participants were enrolled. There was no significant change in whole-body insulin sensitivity or HOMA-IR from baseline or between groups. Total cholesterol increased significantly, by 6.6% with FPV and 10.9% with LPV. The changes in lipids and lipoprotein subfractions were similar between groups with increases in triglycerides, very low-density lipoprotein (VLDL) and chylomicrons, and low-density lipoprotein (LDL) particles. Although the total high-density lipoprotein (HDL) particles were not significantly altered, a decrease in small HDL particles was seen. Changes in VLDL and chylomicron particles in both groups and triglycerides and small HDL particles in the LPV group were statistically significant.
Conclusions
In HIV-type-1-positive men initiating antiretroviral therapy with FPV- or LPV-based regimens, there were no significant changes in whole-body insulin sensitivity after 2 weeks. A proatherogenic lipid pro-file characterized by increases in triglycerides, VLDL and chylomicron particles and LDL particles, and a decrease in small HDL particles, was observed in both groups.
References
1.
GrinspoonS., CarrA.Cardiovascular risk and body-fat abnormalities in HIV-infected adults.N Engl J Med2005; 352: 48–62.
2.
DeFronzoR.A., TobinJ.D., AndresR.Glucose clamp technique: a method for quantifying insulin secretion and resistance.Am J Physiol1979; 237: E214–E223.
LeeG.A., RaoM., MulliganK.Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.AIDS2007; 21: 2183–2190.
5.
NoorM.A., LoJ.C., MulliganK.Metabolic effects of indinavir in healthy HIV-seronegative men.AIDS2001; 15: F11–F18.
6.
NoorM.A., SeneviratneT., AweekaF.T.Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.AIDS2002; 16: F1–F8.
7.
NoorM.A., FlintO.P., MaaJ-F, ParkerR.A.Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.AIDS2006; 20: 1813–1821.
8.
BlümerR.M., van VonderenM.G., SutinenJ.Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.AIDS2008; 22: 227–236.
9.
FleischmanA., JohnsenS., SystromD.M.Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.Am J Physiol Endocrinol Metab2007; 292: E1666–E1673.
10.
BrownT.T., LiX., ColeS.R.Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.AIDS2005; 19: 1375–1383.
11.
MatthewsD.R., HoskerJ.P., RudenskiA.S.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia1985; 28: 412–419.
12.
British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association.JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice.Heart2005; 91 Suppl 5: v1–v52.
13.
DickinsonL., RobinsonL., TjiaJ., KhooS., BackD.Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci2005; 829: 82–90.
14.
La PorteC.T.L., BackD.J., BlaschkeT.Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.Rev Antivir Ther2006; 3: 4–14.
NoorM.A., ParkerR.A., O'MaraE.The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.AIDS2004; 18: 2137–2144.
17.
RandellP., JacksonA., MandaliaS., TaylorJ., MoyleG.The impact of raltegravir and lopinavir/ritonavir on lipids, adiponectin and peripheral glucose disposal in HIV negative subjects.5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract TUPEB171.
18.
DubeM.P., ShenC., GreenwaldM., Mather KierenJ.No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.Clin Infect Dis2008; 47: 567–574.
19.
De WitS., SabinC.A., WeberR.Incidence and risk factors for new-onset diabetes in HIV-infected patients.Diabetes Care2008; 31: 1224–1229.
20.
ShlayJ.C., VisnegarwalaF., BartschG.Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs abacavir and lamivudine.J Acquir Immune Defic Syndr2005; 38: 147–155.
21.
RandellP.A., JacksonA.G., ZhongL., YaleK., MoyleG.J.The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.Antivir Ther2010; 15: 227–233.
22.
JacksonA., PatelN., LoG., GazzardB., MoyleG.Effects of atazanavir or saquinavir QD with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal; a randomised open-label study.14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Poster 818.
23.
CarrA., RitzhauptA., ZhangW.Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.AIDS2008; 22: 2313–2321.
24.
DubeM.P., QianD., Edmondson-MelanconH.Intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.Clin Infect Dis2002; 35: 475–481.
25.
van VonderenM.G., BlümerR.M., HassinkE.A.M.Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy.J Acquir Immune Defic Syndr2010; 53: 186–193.
26.
KedzierskaK., CroweS.M.Cytokines and HIV-1: interactions and clinical implications.Antivir Chem Chemother2001; 12: 133–150.
27.
BastardJ-P, MaachiM., LagathuC.Recent advances in the relationship between obesity, inflammation, and insulin resistance.Eur Cytokine Netw2006; 17: 4–12.
28.
JeyarajahE.J., CromwellW.C., OtvosJ.D.Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.Clin Lab Med2006; 26: 847–870.
29.
KullerL., ArnoldA., TracyR.Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study.Arterioscler Thromb Vasc Biol2002; 22: 1175–1180.
30.
RiddlerS.A., LiX., OtvosJ.Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.J Acquir Immune Defic Syndr2008; 48: 281–288.
31.
DuprezD., INSIGHT/SMART Group. High-density lipoprotein particles but not low-density lipoprotein particles predict cardiovascular disease events in HIV patients: Strategies for Management of ART Study.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009. Montreal, QC, Canada. Abstract 149.
32.
Collot-TeixeiraS., LorenzoF.D., WatersL.Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression.Clin Pharmacol Ther2009; 85: 375–378.
33.
ShafranS.D., MashinterL.D., RobertsS.E.The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.HIV Med2005; 6: 421–425.
34.
HillA., van der LugtJ., SawyerW., BoffitoM.How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.AIDS2009; 23: 2237–2245.
